Autologous haematopoietic stem cell transplantation provides a novel therapeutic option for advanced progressive multiple sclerosis, shown to result in sustained progressionfree periods, improved magnetic resonance image (MRI) appearances and increased quality of life in multicentre phase 2 studies.
1-3 Previous reports have documented mild transplant-related adverse events (including mild fever, viral infections and hepatitis). We report the occurrence of acute neurological deterioration associated with significant pyrexia during transplantation.
A 28-year-old man presented in 2003 with impaired balance, dysarthria and right-sided numbness. He reported an isolated episode of vertigo 3 years earlier. Cranial MRI showed white matter abnormalities in keeping with multiple sclerosis and visual evoked potentials that were bilaterally delayed, and CSF (cerebrospinal fluid) examination demonstrated oligoclonal banding. Subsequently, his illness ran an aggressive relapsing remitting course that failed to respond to corticosteroids, interferon-b, glatiramer acetate and mitoxantrone, with a rapid decline in his Expanded Disability Status Score 4 from 4.0 to 6.5 over 2 years. In view of his aggressive disease and lack of response to conventional therapy, he was referred for autologous transplantation. A repeat cranial MRI pre-transplant showed extensive white matter changes affecting both cerebral and cerebellar hemispheres extending to the midbrain, pons and the medulla with no evidence of gadolinium enhancement.
Peripheral blood stem cells were mobilized with cyclophosphamide 4 g m À2 plus granulocyte colony-stimulating factor 300 mg day À1 and prednisolone 5 mg kg À1 without incident. Transplant conditioning was with BEAM (BCNU 300 mg m À2 day À7; cytosine arabinoside 200 mg m À2 days À6 to À3; etoposide 200 mg m À2 days À6 to À3; and melphalan 140 mg m À2 day À2) as previously described.
1
Intensive transplant induction regimens are associated with tissue damage and generation of large amounts of proinflammatory cytokines. Intravenous cyclosporine A (1 mg kg À1 ) was therefore administered during conditioning to prevent neurological deterioration due to cytokine release.
1 Peripheral blood stem cells were infused on day 0 (CD34 þ cell dose 6.1 Â 10 6 kg
À1
). Due to the potential risk of neurological adverse events following administration of granulocyte colony-stimulating factor, 6 it was not given following transplantation. Rabbit ATG (thymoglobulin, genzyme, 5 mg kg
) was administered on days þ 1 and þ 2 for in vivo T-cell depletion.
1 Although prednisolone 5 mg kg À1 was administered concurrently with ATG, significant fevers were observed during infusion, suggesting that this dose of steroid may not be adequate to prevent the associated cytokine release. While febrile, rapid neurological deterioration was noted with progressive diplopia and impaired abduction of the left eye, dysarthria, dysphagia with nasal aspiration, ataxia and urinary retention. Empiric broad-spectrum antibiotics were administered, but all cultures remained negative. Following completion of ATG, pyrexia resolved with a rapid resolution of the new neurological symptoms. A repeat cranial MRI scan showed no new lesions and no evidence of enhancement. The remainder of his transplant course was unremarkable and was complicated only by mild mucositis with no further febrile episodes. At the time of discharge, neurological features had returned to their pre-transplant baseline and subsequently the patient made a good progressive post transplant recovery to beyond day þ 100. There were no further neurological events and Expanded Disability Status Score at day 100 was 6.0. His MRI appearance has remained unchanged. Wilhelm Uhthoff 7 first described a temporary worsening of vision following exercise in patients with optic neuritis. Temperature-dependent worsening of neurological symptoms occurs in up to 80% of patients with multiple sclerosis, 8 and the mechanism involves conduction block of partially demyelinated axons. 9 Importantly, the effects are transient and lowering of body temperature is associated with resolution of deficits. 10 With the increased awareness of the immunomodulatory properties of autologous transplantation for the therapy of severe autoimmune diseases, 11 transplant physicians must be aware of unfamiliar disease manifestations that may be seen when treating diseases outside their normal practice. 
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